With box warnings

Without box warnings

Branded

Generic

2 results

arcalyst
(rilonacept)
Kiniksa Pharmaceuticals (UK), Ltd.
Usage: ARCALYST (rilonacept) is indicated for treating Cryopyrin-Associated Periodic Syndromes (CAPS) in patients 12 years and older, maintaining remission of Deficiency of Interleukin-1 Receptor Antagonist (DIRA) in patients weighing at least 10 kg, and for managing recurrent pericarditis in patients 12 years and older.
kineret
(anakinra)
Swedish Orphan Biovitrum AB (publ)
Usage: KINERET is indicated for reducing signs and symptoms and slowing structural damage in moderately to severely active rheumatoid arthritis in adults who have failed previous DMARDs. It is also used to treat Neonatal-Onset Multisystem Inflammatory Disease and Deficiency of Interleukin-1 Receptor Antagonist.

Medications for Interleukin 1 Receptor Antagonist Deficiency

arcalyst